Information Provided By: 
Fly News Breaks for November 6, 2018
ALKS
Nov 6, 2018 | 07:30 EDT
Cantor Fitzgerald analyst William Tanner lowered his price target for Alkermes to $41 from $46 and reiterates a Neutral rating on the shares. The FDA advisory panel view of the ALKS 5461 NDA is a "major setback" not only for the drug but also to the ability of Alkermes to convince investors that the company can develop proprietary therapies of meaningful commercial potential, Tanner tells investors in a research note. He now believes the upcoming ALKS-3831 Enlighten-2 data release "looms larger" after the ALKS 5461 panel decision.
News For ALKS From the Last 2 Days
ALKS
Apr 15, 2024 | 07:36 EDT
UBS lowered the firm's price target on Alkermes to $23 from $25 and keeps a Sell rating on the shares. UBS believes Alkermes stock will likely continue to underperform, as the FY24 guidance seems unachievable and there are no pipeline catalysts remaining for the year, the analyst tells investors in a research note.
